Enhanced Co-Expression Extrapolation (COXEN) Gene Selection Method for Building Anti-Cancer Drug Response Prediction Models
- PMID: 32933072
- PMCID: PMC7565427
- DOI: 10.3390/genes11091070
Enhanced Co-Expression Extrapolation (COXEN) Gene Selection Method for Building Anti-Cancer Drug Response Prediction Models
Abstract
The co-expression extrapolation (COXEN) method has been successfully used in multiple studies to select genes for predicting the response of tumor cells to a specific drug treatment. Here, we enhance the COXEN method to select genes that are predictive of the efficacies of multiple drugs for building general drug response prediction models that are not specific to a particular drug. The enhanced COXEN method first ranks the genes according to their prediction power for each individual drug and then takes a union of top predictive genes of all the drugs, among which the algorithm further selects genes whose co-expression patterns are well preserved between cancer cases for building prediction models. We apply the proposed method on benchmark in vitro drug screening datasets and compare the performance of prediction models built based on the genes selected by the enhanced COXEN method to that of models built on genes selected by the original COXEN method and randomly picked genes. Models built with the enhanced COXEN method always present a statistically significantly improved prediction performance (adjusted p-value ≤ 0.05). Our results demonstrate the enhanced COXEN method can dramatically increase the power of gene expression data for predicting drug response.
Keywords: co-expression extrapolation (COXEN); gene selection; general drug response prediction model; precision oncology.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures



Similar articles
-
The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.Cancer Res. 2010 Mar 1;70(5):1753-8. doi: 10.1158/0008-5472.CAN-09-3562. Epub 2010 Feb 16. Cancer Res. 2010. PMID: 20160033 Free PMC article. Review.
-
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery.Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13086-91. doi: 10.1073/pnas.0610292104. Epub 2007 Jul 31. Proc Natl Acad Sci U S A. 2007. PMID: 17666531 Free PMC article.
-
Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents.Neoplasia. 2011 Jan;13(1):72-80. doi: 10.1593/neo.101214. Neoplasia. 2011. PMID: 21253455 Free PMC article.
-
Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy.Assay Drug Dev Technol. 2015 Dec;13(10):623-7. doi: 10.1089/adt.2015.29012.dlgdrrr. Assay Drug Dev Technol. 2015. PMID: 26690765 Free PMC article.
-
New tools for old drugs: Functional genetic screens to optimize current chemotherapy.Drug Resist Updat. 2018 Jan;36:30-46. doi: 10.1016/j.drup.2018.01.001. Epub 2018 Jan 12. Drug Resist Updat. 2018. PMID: 29499836 Free PMC article. Review.
Cited by
-
Integration of Computational Docking into Anti-Cancer Drug Response Prediction Models.Cancers (Basel). 2023 Dec 21;16(1):50. doi: 10.3390/cancers16010050. Cancers (Basel). 2023. PMID: 38201477 Free PMC article.
-
Converting tabular data into images for deep learning with convolutional neural networks.Sci Rep. 2021 May 31;11(1):11325. doi: 10.1038/s41598-021-90923-y. Sci Rep. 2021. PMID: 34059739 Free PMC article.
-
A context-aware deconfounding autoencoder for robust prediction of personalized clinical drug response from cell-line compound screening.Nat Mach Intell. 2022 Oct;4(10):879-892. doi: 10.1038/s42256-022-00541-0. Epub 2022 Oct 17. Nat Mach Intell. 2022. PMID: 38895093 Free PMC article.
-
Data imbalance in drug response prediction: multi-objective optimization approach in deep learning setting.Brief Bioinform. 2025 Mar 4;26(2):bbaf134. doi: 10.1093/bib/bbaf134. Brief Bioinform. 2025. PMID: 40178282 Free PMC article.
-
Biomarker challenges in the pursuit of personalized neoadjuvant chemotherapy for muscle-invasive bladder cancer: conclusions from SWOG S1314.Transl Androl Urol. 2024 Mar 31;13(3):458-462. doi: 10.21037/tau-23-620. Epub 2024 Mar 12. Transl Androl Urol. 2024. PMID: 38590957 Free PMC article. No abstract available.
References
-
- Menden M., Wang D., Mason M., Szalai B., Bulusu K., Guan Y., Yu T., Kang J., Jeon M., Wolfinger R., et al. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. Nat. Commun. 2019;10:2674. doi: 10.1038/s41467-019-09799-2. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical